Could a multiple sclerosis drug sharpen memory in depression?

NCT ID NCT06751784

Recruiting now Symptom relief Sponsor: University of Basel Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether fampridine, a drug used for walking problems in multiple sclerosis, can improve working memory in people with mild to moderate depression. About 38 adults will receive both fampridine and a placebo in random order to see if the drug helps them perform better on memory tasks. The goal is to find a new way to treat cognitive issues that often come with depression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fampridine (a potassium channel blocker)
What this could lead to: If it works, this could point toward a treatment for memory problems in people with depression.
What could go wrong: This is a small early-phase trial with only 38 people. It may not show a clear benefit, and fampridine can cause side effects like dizziness or seizures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

depressive disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MILD DEPRESSION MILD TO MODERATE DEPRESSION WORKING MEMORY

Contacts and locations

Locations

University of Basel, Reserach Cluster Molecular and Cognitive Neurosciences
RECRUITING

Basel, Canton of Basel-City, 4055, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.